期刊文献+

合并肾功能不全的多发性骨髓瘤治疗进展

下载PDF
导出
摘要 多发性骨髓瘤(multiplemyeloma,MM)患者约20%~40%在疾病发展的某个阶段合并肾功能不全,这些伴有肾功能不全患者对传统化疗反应差,早期病死率高,生存时间明显低于不伴肾功能不全的患者。本文对此类患者的治疗进展作一综述。
作者 宋慧 刘凌波
出处 《临床肾脏病杂志》 2013年第5期199-201,共3页 Journal Of Clinical Nephrology
  • 相关文献

参考文献18

  • 1Hutchison CA, batuman V, brehrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol,2011,8:43-51.
  • 2陈楠.多发性骨髓瘤肾脏损害诊断和治疗[J].内科理论与实践,2007,2(6):373-375. 被引量:8
  • 3Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med, 2007,7 : 83-97.
  • 4Stringer S, Basnayake K, Hutchison C, et al. Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney). Bone Marrow Res. Volume 2011: Article ID 493697,9 pages, doi : 10. 1155/2011/493697.
  • 5王丽娟(综述),宋强(审校).复发性与难治性多发性骨髓瘤的治疗进展[J].国际输血及血液学杂志,2011,34(6):517-522. 被引量:3
  • 6Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in com- bination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haema- tol,2004,73:98-103.
  • 7王小山(综述),陈钰(审校).多发性骨髓瘤治疗进展[J].国际输血及血液学杂志,2011,34(5):349-352. 被引量:4
  • 8Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or re- fractory multiple myeloma patients with impaired renal function. Cancer, 2010,116:3807-3814.
  • 9Klein U, Neben K, Hielscher T, et al. Lenalidomide in combina- tion with dexamethasone: Effective regimen in patients with re- lapsed or refractory multiple myeloma complicated by renal im- pairment. Ann Hematol, 2011,90 : 429-439.
  • 10DAmato R J, Loughnan MS, Flynn E, et al. Thalidomide is an in- hibitor of angiogenesis. Proc Natl Acad Sci USA. 1994,91:4082- 4O85.

二级参考文献77

  • 1Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma, 2007,48(2) :337-341.
  • 2Chanan-KhanAA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure:a multicenter retrospective study. Blood,2007, 109 (6):2604-2606.
  • 3Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone- containing regimes and the impact of novel agents. Haematologica, 2007, 92(4):546-549.
  • 4Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention with new insights from in vitro and in vivo models of renal injury. Am J Nephrol,2009, 22(1) :17-28.
  • 5Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol,2010, 84(3) :223-228.
  • 6Dimopoulos MA, Roussou M, Gavriatopoulou M, et aI. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive faetors. Clin Lymphoma Myeloma, 2009, 9 (4) : 302- 306.
  • 7Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can he reversed by bortezomib-doxorubicin- dexamethasone in multiple myeloma:results of a phase Ⅱ study. J Clin Oncol,2010, 28(30) :4635-4641.
  • 8Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res, 2010, 34(10):1395- 1397.
  • 9Li J, Zhou DB, Jiao L, et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma, 2009,9 (5) : 394-398.
  • 10Qayum A, Aleem A, AI Diab AR, et al. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi J Kidney Dis Transpl, 2010, 21 (1) : 63-68.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部